WCC Biomedical recently took part in the PharmaEd Microneedle and Intradermal Delivery Forum, a leading international gathering that brought together pharmaceutical companies, CDMOs, and academic researchers from the United States, Europe, and Asia to discuss the latest advances in transdermal and intradermal drug delivery.
Founded in 2014, WCC Biomedical has established itself as a Taiwan-based leader in microneedle array patch (MAP) development and large-scale manufacturing. At this year’s forum, the company presented its WINMAP mini platform and its production capabilities to an audience of global industry leaders, sparking substantive conversations about the next stage of needle-free drug delivery.
A Platform Built for Scale
One of the central themes at the forum was the industry’s shift from lab-scale microneedle prototypes toward commercially viable, large-volume manufacturing. This is precisely the gap WCC Biomedical set out to close. With an integrated capability spanning formulation, patch design, and mass production, WCC is one of a small number of organizations in the world equipped to carry a microneedle concept from early-stage development through to commercial-scale output.
During the two-day forum, WCC engaged with pharmaceutical companies exploring biologic and peptide delivery through microneedles, as well as with academic researchers interested in leveraging WCC’s platform technology to accelerate their own development timelines. These discussions reinforced a trend that WCC has long anticipated: as the pipeline of biologics, peptides, and vaccine candidates suited to microneedle delivery grows, manufacturing scale-up — not just formulation science — will determine which technologies actually reach patients.
Staying Close to the Regulatory Conversation
The forum also underscored how the regulatory landscape for microneedle products continues to evolve, with increasing dialogue between developers and regulatory authorities shaping expectations around quality, safety, and manufacturing standards. WCC Biomedical continues to track these developments closely, ensuring that its manufacturing processes and quality systems remain aligned with the direction the field is heading.
Looking Ahead
The connections made at this year’s forum reflect the growing global interest in microneedle-based delivery, and WCC Biomedical is proud to be recognized as a manufacturing partner capable of turning that interest into real-world products. The company will continue to expand its platform technology and production capacity to support partners bringing the next generation of needle-free therapies to market.
To learn more about WCC Biomedical’s microneedle platform and manufacturing capabilities, please contact us through our website.